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Acute graft-versus-host disease (aGVHD) is a severe complication of allogeneic hematopoietic stem cell transplan-
tation. The role of Th17 cells in its pathophysiology remains a matter of debate. In this study, we assessed whether
enrichment of human peripheral blood mononuclear cells (PBMCs) with in vitro Th17-polarized CD4+ T cells
would exacerbate xenogeneic GVHD (xGVHD) into NOD-scid IL-2Rg null (NSG) mice. Naive human CD4+ T cells
were stimulated under Th17-skewing conditions for 8 to 10 days and then coinjected in NSG mice with fresh
PBMCs from the same donor. We observed that Th17-polarized cells engrafted and migrated toward xGVHD tar-
get organs. They also acquired a double-expressing IL-17A+IFNg+ proﬁle in vivo. Importantly, cotransfer of Th17-
polarized cells (1£ 106) with PBMCs (1£ 106) exacerbated xGVHD compared with transplantation of PBMCs alone
(2£ 106). Furthermore, PBMC cotransfer with Th17-polarized cells was more potent for xGVHD induction than
cotransfer with naive CD4+ T cells stimulated in nonpolarizing conditions (Th0 cells, 1£ 106 + 1£ 106 PBMCs) or
with Th1-polarized cells (1£ 106 + 1£ 106 PBMCs). In summary, our results suggest that human Th17-polarized
cells can cooperate with PBMCs and be pathogenic in the NSG xGVHD model.
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Graft-versus-host disease
Xenogeneic
NSG
Th17
IL-17A
Graft-versus-tumorgments on page 214.
uests: Sophie Servais, MD, PhD, University
ivision of Hematology, CHU Sart-Tilman
e.be (S. Servais).
.10.007
for Blood and Marrow Transplantation.INTRODUCTION
Acute graft-versus-host disease (aGVHD) remains a major
cause of transplantation-related mortality after allogeneic
hematopoietic stem cell transplantation (alloHSCT). The
immunobiology of aGVHD is complex and involves an intricate
network of immune cells [1-3]. Among these cells, donor
T cells are considered the main drivers and effectors of aGVHD
reactions, as demonstrated by the low incidence of aGVHD
observed in patients who undergo T cell-depleted alloHSCT
[4]. During aGVHD, donor T cells react against host foreign
antigen/HLA complexes through both direct and indirect allor-
ecognition via their T cell receptors, and proliferate through
engagement of costimulatory molecules. The third signal is
provided by cytokines that further promote T cell polarization.
Whereas interleukin (IL)-12 or IL-4 stimulation induces dif-
ferentiation toward interferon (IFN)-g-producing T helper (Th)1
cells or IL-4-producing Th2 cells, respectively, transforminggrowth factor (TGF)-b, IL-6, IL-1b, IL-21, and IL-23 drive the
development of IL-17-producing Th17 cells [5]. Th17 cells are
now widely considered key mediators in several inﬂammatory
diseases, such as experimental autoimmune encephalomyelitis
and colitis. Whether these cells are also involved in the patho-
physiology of alloimmune inﬂammation in aGVHD has remained
an open question. In fact, although a growing amount of data
support a role of Th17 cells in aGVHD in preclinical mouse mod-
els [6-11], studies in humans have reported conﬂicting results,
suggesting [12-15] or dismissing [16-18] their involvement.
Signiﬁcant differences exist between human and murine
immune systems, and a major limitation of animal models
remains their limited predictive value in human diseases [19]. An
example can be drawn from the recent experience with IL-17
blockade in inﬂammatory bowel disorders, in which several stud-
ies in mice had linked IL-17 to the pathogenesis of colitis, but
treatment with anti-IL-17A and anti-IL-17RA antibodies was
found to ultimately exacerbate the disease in humans
[20-22]. To bridge these limitations, humanized mouse models
may serve as an attractive intermediate platform between animal
models and projection to the clinic by offering the opportunity to
study the behavior of human immune cells in vivo.
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els of xenogeneic GVHD (xGVHD) have been developed
via the injection of human peripheral blood mononuclear
cells (PBMCs) into severely immunodeﬁcient NOD/Shi-scid
IL2rg-null (NOG) or NOD/LtSz-scid IL2rg-null (NSG) mice
[23-32]. These models are T cell dependent, and main
triggers of T cell activation and expansion are xenogeneic
MHC (H-2) class I and class II molecules [23,30,33,34] and
xenogeneic costimulatory signals [27,35]. Previous studies
have demonstrated a crucial interplay between CD4+ and
CD8+ T cells during xGVHD [23,35]; however, the concrete
role of individual T cell subsets has not yet been fully
elucidated.
More speciﬁcally, little is known about the potential implica-
tion of Th17 cells in xGVHD pathogenesis in NOG/NSG mice.
Indeed, although some groups have reported the presence of
human Th17 cells at the time of xGVHD, Th17 cells represent
only a small fraction of CD4+ T cells in blood, lymphoid tissue,
and xGVHD target organs [23,26,34,36]. This may be due to low
levels of human pro-Th17 cytokines in that model, which limit
naive cell polarization toward Th17 fate in vivo after their trans-
fer in mice. For example, low serum levels of human IL-6 were
measured in xGVHD mice [37,38], and murine IL-6 does not bind
to the human IL-6 receptor [39,40]. However, indirect observa-
tions,D29X Xhave suggested that Th17 cells, albeit infrequent in num-
bers, could participate in xGVHD pathogenesis [36,41]. Among
these observations, IL-21 blockade was found to decrease IL-17-
producing cells in target organs and to signiﬁcantly reduce
xGVHD [36]. Nevertheless, it is difﬁcult to conceive a Th17-
dependent pathway as the exclusive mechanism for xGVHD pre-
vention by IL-21 blockade, considering that this strategy also
increases regulatory T cell (Treg) numbers and decreases the pro-
portions of IFNg- and granzyme B-secreting T cells. More
recently, Ito et al [23] reported that after transplantation of puri-
ﬁed CD4+ human T cells into NOG mice, Th17 cells accumulated
in the skin and induced IL-17-mediated skin inﬂammation and
lesions.
In the present study, we explored the potency of in vitro
Th17-polarized human CD4+ T cells to participate in xGVHD
in NSG mice. Because Th17 cells do not mediate their immune
effects independently but rather work in concert with other
D3 0X Xcells, we evaluated whether the administration of Th17-
polarized cells could cooperate with whole PBMCs in the
induction of xGVHD.MATERIALS ANDMETHODS
In Vitro Polarization of Human Naive CD4+ T Cells
Humanwhole peripheral blood (PB) was obtained from healthy adult vol-
unteers (age 20 to 35 years) following written informed consent. PBMCs were
isolated by Ficoll-Paque density centrifugation (GE Healthcare, Freiburg, Ger-
many). Naive CD4+CD45RA+CD62L+CD25¡ cells were sorted by high-speed
ﬂow cytometry (FACSAria III; BD Biosciences, San Jose, CA) to >98% purity as
veriﬁed by postsorting analysis. Sorted cells were plated in 96-well round-
bottomed plates at a density of 1£ 105 cells per well in XVIVO 15 media
(Lonza, Basel, Switzerland), along with anti-CD3/anti-CD28- coated beads
(1:1 bead cell ratio; Invitrogen, Carlsbad, CA). Depending on the type of
experiment, cells were cultured in nonpolarizing conditions (no cytokines),
Th17-polarizing conditions (25 ng/mL rhuIL-6, 6.25 ng/mL rhuTGF-b1,
12.5 ng/mL rhuIL-1b, 25 ng/mL rhuIL-21, and 25 ng/mL rhuIL-23 [all from
PeproTech, Rocky Hill, NJ], 500 ng/mL anti-human IFNg antibody [NIB42;
BioLegend, San Diego, CA], 500 ng/mL anti-human IL-2 antibody [5334; R&D
Systems, Minneapolis, MN], and 40 mM NaCl), as described previously [42],
or Th1-polarizing conditions (20 ng/mL rhuIL-12p70, 5 ng/ml rhuIL-2 [both
from PeproTech] and 500 ng/ml anti-human IL-4 antibody [8D4-8; BioLe-
gend]). Medium was changed every 3 to 4 days, and cells were harvested
after a total of 8 to 10 days of culture. Cell suspensions obtained at harvest
were designated as nonpolarized Th0 cells, Th17-polarized cells, and
Th1-polarized cells.Induction of xGVHD in NSG Mice
Immunodeﬁcient NSG mice were used for all experiments (see Supple-
mentary Materials and Methods). For xGVHD induction, 8- to 12-week-old
NSG mice were irradiated (2.5 Gy total body irradiation, [137Cs source
gamma cell irradiator 40; Nordion, Ottawa, Canada]) on day -1 and under-
went transplantation (lateral tail vein injection) on day 0 with either PBMCs
alone or PBMCs combined with in vitro cultured CD4+ T cells (Th17-polarized,
Th1-polarized, or nonpolarized Th0 cells) from the same donor. Mice were
monitored daily for general well-being and weighed 3 times weekly. The
severity of xGVHD was also recorded thrice weekly using a scoring system
that incorporates 4 clinical parameters—weight loss, hunching, lethargy, and
anemia—each scored from 0 (absent) to 2 (severely marked), as described
previously [25,26]. An xGVHD score 6/8 or weight loss 20% were consid-
ered ethical limit points, as requested by our Institutional Ethics Committee.
Mice were euthanized when reaching the ethical limit point or earlier if sacri-
ﬁce was planned at a predeﬁned time point. Depending on the experiment,
serial PB samples were collected at days +14 and +21 after human cell trans-
plantation. Furthermore, at the time of necropsy, PB, spleen, bone marrow
(BM), liver, and lungs were harvested as well. Methods used for mononuclear
cell isolation from peripheral organs are described in Supplementary Mate-
rials and Methods. Within each individual experiment, all groups of mice
underwent transplantation with cells from the same donor. To limit interdo-
nor variability, most of the experiments were replicated with at least 2 differ-
ent donors. All experimental protocols and procedures were approved by the
Institutional Animal Care and Use Ethics Committee of the University of Liege
(certiﬁcation 1544).
Graft-versus-Tumor Effects
To investigate graft-versus-tumor (GVT) effects, we used THP-1 cells
(a human tumoral cell line derived from an acute monocytic leukemia patient,
TIB-202; American Type Culture Collection, Manassas, VA) transfected with a len-
tiviral vector containing reporter genes coding ﬁreﬂy luciferase (THP-1-luc), as
described previously [26]. Eight- to 12-week-old NSG mice were irradiated on
day -1 and underwent transplantation on day 0 with either PBMCs alone or with
PBMCs combined with in vitro cultured CD4+ T cells (Th17-polarized, Th1-polar-
ized, or nonpolarized Th0 cells) from the same donor (see above for the xGVHD
model). At 14 days after transplantation, mice also received an s.c. injection (in
the left ﬂank) of 1£ 106 THP-1-luc cells suspended in 200 mL of a 50/50 PBS
(Lonza) and Matrigel (Corning, Tewksbury, MA) solution. This enables THP-1-luc
cells to proliferate locally and to form subcutaneous tumors at the site of injec-
tion. Tumor growth was evaluated by measuring bioluminescence at day + 21
after THP-1-luc injection (see Supplementary Materials and Methods). At
day + 49 after THP-1-luc injection, mice were sacriﬁced, and tumors were dis-
sected and weighted. As a positive control, another group of mice also received s.
c. injections of THP-1-luc cells without receiving either irradiation or transplanta-
tion with human immune cells (THP-1 control group).
Flow Cytometry Analyses
Mononuclear cells were stained with various combinations of ﬂuorescence-
conjugated anti-human antibodies (Supplementary Materials and Methods).
For extracellular staining, cells were incubated with appropriate antibodies for
20 minutes at 4°C and then washed twice with PBS and 3% FBS. For FOXP3 and
cytokine intracellular staining, cells were ﬁxed and permeabilized with the
FOXP3 Staining Buffer Set (Thermo Fisher Scientiﬁc , Waltham, MA), according to
the manufacturer's instructions. For intracellular cytokine staining, cells were
stimulated for 4h with Cell Stimulation Cocktail Plus Protein Transport Inhibitors
(Invitrogen) in XVIVO 15 media (Lonza), followed by ﬁxation, permeabilization,
and stainingwith appropriate antibodies according to themanufacturer's instruc-
tions. Data were acquired using a FACSCanto II ﬂow cytometer (BD Biosciences)
and analyzed with FlowJo 7.0 (TreeStar, Ashland, OR). For absolute count calcula-
tion, absolute white blood cells were countedwith a Sysmex XS-800i hematology
analyzer (Sysmex, Norderstedt, Germany) before antibody staining.
Other Analyses
The RT-qPCR assay, carboxyﬂuorescein diacetate succinimidyl ester (CFSE)
dilution assay, quantiﬁcation of serum cytokine levels, histology, and immuno-
histochemistry are described in Supplementary Materials and Methods.
Statistical Analyses
Data are presented as individual observations with median, unless speci-
ﬁed otherwise. Comparisons between groups were made with 1-way analysis
of variance (ANOVA) with the Scheffe post hoc procedure. To normalize their
distribution, some variables underwent prior logarithmic or square root
transformation. Survival curves were plotted using Kaplan-Meier estimates,
and comparisons between groups were done using the log-rank test. Weight
loss over time was analyzed using a generalized linear mixed model, and the
evolution of xGVHD score over time was analyzed using a repeated ordinal
logistic model. Weight and xGVHD score at death were carried forward after
death. Multivariate Cox models adjusted for PBMC donor and mouse sex and
weight were also performed for most of the analyses. Results were
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ried out with SAS version 9.4 (SAS Institute, Cary, NC), and ﬁgures were pre-
pared with Prism 5.0 (GraphPad Software, La Jolla, CA).RESULTS
In Vitro Th17-Polarized Cells
We examined the secreting proﬁle of human naive CD4+ T cells
after 8 to 10 days of in vitro stimulation under the Th17-polarizing
condition and under the nonpolarizing (Th0) condition (Figure 1).
Whereas Th0 condition naturally resulted in an IFNg+IL-17A¡
(Th1)-expressing proﬁle in a substantial proportion of cells, cell
suspensions obtained from Th17-polarizing cultures were charac-
terized by amedian of 10% (range, 7% to 38%) of IL-17A-expressing
cells and a low proportion of IFNg+IL-17A¡ cells (median 2%;
range, 1% to 8%) (Figure 1A and B). Most IL-17A+CD4+ cells did not
coexpress IFNg. Cells from Th17-polarizing cultures also displayed
higher relative expression of IL17A, RORC (Th17-speciﬁc master
transcription factor), and IL23R mRNA compared with Th0 cells,
along with minimal expression of TBX21 (TBET) mRNA (Figure 1C).
In both conditions, the expression of IL-4 (a cytokine of Th2 line-
age) was minimal (<2%) (data not shown). Taken together, these
results show that Th17-polarized cells could be generated from
human naive CD4+ T cells in vitro. However, in contrast to previous
reports with murine cells [7,43-45], a signiﬁcant fraction of human
CD4+ cells remained IL-17A¡IFNg¡IL-4¡ unpolarized after 8 to
10 days of culture.
No good correlation was obtained between IL-17A intracellular
staining and surface expression of CCR6 and CD161, 2 usual
markers of Th17 cells [46] (data not shown). Because this pre-
cluded the possibility to perform CCR6+CD161+ FACS sorting of
Th17 cells, we decided to use total cell suspension for mouse injec-
tions. To ensure the transfer of at least 100,000 IL-17A+ cells per
recipient mouse, we elected to use only Th17-polarized cellFigure 1. Human naive T cells cultured under Th17-polarizing and nonpolarizing co
coated beads in either Th0-nonpolarizing (no cytokine) or Th17-polarizing (Th17-ske
cells were harvested for ﬂow cytometry and/or RT-qPCR analyses. (A) Representative F
among CD4+ cells (ﬂow cytometry). (C) relative mRNA expression of RORC, IL-17A, IL-2
cultured in the Th0-nonpolarizing condition, and gray squares denote cells cultured in
parisons between the 2 conditions.suspensions with a minimal yield of 10% of IL-17A+CD4+ cells. Spe-
ciﬁcally, this was achieved in 60% of cultures, and the Th17-polar-
ized cell suspensions used in mouse experiments described below
had amedian of 21.5% (range, 10% to 38%) IL-17A+ CD4+ T cells.
We also checked that in vitro generated cells were not
exhausted and were able to undergo additional rounds of divi-
sion in vivo after transfer in NSG mice. Th17-polarized and
nonpolarized Th0 cells, as well as CD4+ T cells derived from
freshly isolated PBMCs (control), were loaded with CFSE and
then transplanted into irradiated NSG mice (4£ 106 cells/
mouse). Mice were sacriﬁced at day +3. Human CD4+ T cells
and CFSE signals were detected in PB as well as in spleen and
peripheral organs at this early time point. Interestingly, cul-
tured cells (and more speciﬁcally, Th17-polarized cells), dem-
onstrated high proliferative activity in vivo after transfer
(Supplementary Figure S1).
Impact of PBMC Cotransplantation with Th17-Polarized Cells
on xGVHD
In a ﬁrst set of experiments, we investigated xGVHD in NSG
mice cotransplanted with PBMCs (1£ 106 per mouse) and
Th17-polarized cells (1£ 106 per mouse, Th17 coinjected group)
and in mice transplanted with 2£ 106 PBMCs (PBMC group). To
prevent interdonor variability, the experiment was replicated
4 times with 4 different donors. As shown in Figure 2A, Th17
coinjection led to signiﬁcantly shorter survival (median survival,
29 days for Th17 coinjected mice versus 53 days for PBMCmice;
P = .015). The higher lethality was conﬁrmed in a multivariate
Cox regression model adjusted for PBMC donor and mouse sex
and weight (hazard ratio [HR], 2.9; 95% CI, 1.4 to 5.9; P = .004).
Similarly, the clinical severity of xGVHD and the rate of weight
loss were also aggravated in Th17 coinjected mice (Figure 2B
and C). Of note, we also observed a signiﬁcant impact of thenditions. Human naive CD4+ T cells were stimulated with anti-CD3/anti-CD28
wing cytokines and hypernatremia) conditions. After 8 to 10 days of culture,
ACS plot of IL-17A versus IFNg. (B) frequencies of IL-17A+ and IL17A¡IFNg+ cells
3R, and TBX21 (TBET) normalized to TBP (RT-qPCR). White triangles denote cells
the Th17-polarized condition. The Wilcoxon rank-sum test was used for com-
Figure 2. Impact of PBMC cotransplantation with Th17-polarized cells on xGVHD. NSG mice were irradiated (2.5 Gy total body irradiation) and underwent transplan-
tation with 2£ 106 PBMCs alone (PBMC mice), with 1£ 106 PBMCs combined with 1£ 106 Th17-polarized cells (Th17 coinjected mice), or with 1£ 106 nonpolarized
Th0 cells (Th0 coinjected mice) from the same donor. (A to C) Comparisons of survival (A), xGVHD score (B), and weight loss (C) between PBMC mice (n = 21) and
Th17 coinjected mice (n = 25). Combined data from 4 replicate experiments with 4 different donors are shown. (D to F) Comparisons of survival (D), xGVHD score (E),
and weight loss (F) in PBMCmice (n = 7), Th17 coinjected mice (n = 10), and Th0 coinjected mice (n = 10). Combined data from 2 replicate experiments with 2 different
donors are shown. (G) xGVHD histopathological scores in liver, lungs, and skin tissue specimens at day +21 after transplantation. (H) Representative pictures (magni-
ﬁcation 10£) of hematoxylin and eosin (H&E) staining of liver, lung, and skin tissues at day +21 in Th17 coinjected mice. Data are from a single experiment with 1
donor, 7 PBMC mice, 8 Th0 coinjected mice, and 9 Th17 coinjected mice. For xGVHD score and weight loss, data are shown as means. P values in parentheses refer to
a multivariate Cox model adjusted for PBMC donor, mouse sex, and weight. For comparisons among PBMC, Th17 coinjected, and Th0 coinjected mice (D-F), global P
values (1-way ANOVA) are shown, along with 2-by-2 group comparisons with the Scheffe post hoc procedure (*P < .05). Black circles denote PBMC mice; gray
squares, Th17 coinjected mice; white triangles, Th0 coinjected mice.
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the multivariate analyses.
We further performed another set of experiments with an
additional comparative group of mice cotransplanted with
PBMCs and nonpolarized Th0 cells (1£ 106 + 1£ 106 per
mouse, Th0 coinjected group). We observed signiﬁcant differ-
ences in survival between groups (univariate analysis, P = .047;
multivariate analysis, P = .012) with increased risk of lethality
for Th17 coinjected mice compared with PBMC mice (HR, 7.1;
95% CI, 1.9 to 26.3, multivariate analysis) and Th0 coinjected
mice (HR, 3.1; 95% CI, 1.1 to 9.1, multivariate analysis). In con-
trast, survival was similar in Th0 coinjected and PBMC mice
(Figure 2D). XGVHD score and weight loss analyses also indi-
cated aggravated xGVHD among Th17 coinjected mice com-
pared with the other 2 groups (Figure 2E and F).
In another set of experiments, we sacriﬁced mice at day +21
after transplantation to assess xGVHD pathology in target tissues
(liver, lungs, and skin) (hematoxylin and eosin [H&E] stain;
Figure 2G and H). In each of these organs, we noted lymphoid
inﬁltrates, tissue lesions (including endotheliitis and alveolar and
bronchial alterations in the lungs; portal tract expansion, endothe-
liitis, and parenchymal alteration in the liver; and epidermal
hyperplasia and epidermal and follicular dyskeratosis in the skin),
and typical signs of xGVHD, such as apoptotic bodies and bile
plugs. When integrating these observations into a xGVHD histo-
pathological scoring system (Supplementary Materials andMethods), we noted trends for higher scores in lungs and skin for
Th17 coinjected mice compared with the other 2 groups, although
the differences did not reach statistical signiﬁcance (Figure 2G).
Regarding the clinical phenotype of xGVHD, no difference was
observed between groups except for extensive areas of fur loss
that developed in some Th17 coinjected mice (Figure 3A). These
cutaneous manifestations occurred after a delay of 40 to 70 days
after human cell transplantation and concerned 4 of the 7 Th17
coinjected mice that survived beyond day + 40. In 2 of these
mice, skin specimens were harvested by the time of necropsy for
histopathological analyses, which revealed severe skin xGVHD
histopathological scores (10.5 and 16.5) with epidermal hyper-
plasia, marked epidermal and follicular dyskeratosis, basal cell
layer vacuolization, and dermal ﬁbrosis (Figure 3B).
Characterization of Circulating Human T Cells in Mice
Cotransplanted with PBMCs and Th17-Polarized Cells
We analyzed human T cells in PB of PBMC mice, Th17 coin-
jected mice, and Th0 coinjected mice at day +14 post-trans-
plantation. Human CD45+ chimerism was similar in all groups
(Figure 4A). In comparison with PBMC mice, we noted higher
CD4+/CD8+ T cell ratio and higher absolute numbers of CD4+ T
cells in PB of Th17 and Th0 coinjected animals (Figure 4B and
D). In Th17-coinjected mice, circulating CD4+ T cells were char-
acterized by a signiﬁcantly higher proportion of IL-17A+ cells
(median, 13.2%) compared with PBMC and Th0 coinjected mice
Figure 3. Late cutaneous manifestations in surviving Th17 coinjected mice. (A) Representative picture of a Th17-coinjected mouse (106 PBMCs + 106 Th17-polarized
cells) at day +40 after transplantation. (B) H&E staining of skin tissues (magniﬁcation 20£) from a Th17-coinjected mouse (106 PBMCs + 106 Th17-polarized cells)
with a cutaneous phenotype, sacriﬁced at day +45 after transplantation.
Figure 4. Circulating human T cells in PB of PBMC, Th17 coinjected and Th0 coinjected mice at day +14 after transplantation. NSG mice were irradiated (2.5 Gy total
body irradiation) and then underwent transplantation with 2£ 106 PBMCs alone (PBMC mice), with 1£ 106 PBMCs combined with 1£ 106 Th17-polarized cells
(Th17 coinjected mice), or with 1£ 106 nonpolarized Th0 cells (Th0 coinjected mice) from the same donor. Peripheral blood samples were collected at day +14 after
transplantation for ﬂow cytometry analyses. (A and B) Human lymphoid chimerism (A) and CD4+/CD8+ human T cell ratio (B); combined data from 3 replicate experi-
ments with 3 different donors. (C to E) Absolute counts of human CD45+ lymphoid cells (C), CD4+ T cells (D), and CD8+ T cells (E); analyses from 1 experiment with a
single donor. Global P values (1-way ANOVA) are shown, along with 2-by-2 group comparisons with the Scheffe post hoc procedure (*P< .05). P values in parentheses
refer to a multivariate Cox model adjusted for PBMC donor, mouse sex, and weight. Prior logarithmic transformation was applied for CD4/CD8 T cell ratio, and prior
square root transformation was applied for absolute numbers of cells. Black circles denote PBMC mice; gray squares, Th17 coinjected mice; white triangles, Th0 coin-
jected mice.
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higher absolute numbers of IL-17A+CD4+ T cells (Supplemen-
tary Figure S2) and higher serum titers of IL-17A were also
measured in Th17 coinjected mice (Figure 5B). Interestingly,
although very few in vitro generated IL-17A+ cells expressed
IFNg (see above), the majority of circulating IL-17A+CD4+ T
cells acquired a double IL-17A+IFNg+ secreting proﬁle in vivo
(Figure 5C and D).
PB from Th17 coinjected mice also revealed a signiﬁcantly
lower proportion of IL-17A¡IFNg+ (Th1) CD4+ T cells compared
to PBMC and Th0 coinjected animals (Figure 5A). Regarding
CD4+CD25+FOXP3+ Treg and TNFa-expressing CD4+ T cells, PB
composition in Th17 coinjected mice was similar to that
observed in Th0 coinjected mice, namely with a lowerproportion of Tregs and a higher proportion of TNFa+CD4+ T
cells compared with PBMC recipients (Figure 5A). TNFa was
expressed by most of IL-17A+ (Th17) and IL-17A¡IFNg+ (Th1)
CD4+ T cells (Figure 5C and D). Finally, no differences in CD8+
T cell subsets were observed among the groups. Most CD8+
T cells were IL-17A¡IFNg+ CD8+ T cells (Tc1) (Figure 5A),
whereas only a very low (<1%) proportion of IL-17A+CD8+ T
cells (Tc17) were detected in all groups (data not shown).
Similar trends were observed when comparing absolute
counts of T cell subsets, with the exception of the number of
IL-17A¡IFNg+ (Th1) cells, which was similar in Th17 coinjected
and PBMC mice, because of higher numbers of circulating total
CD4+ T cells in Th17 coinjected mice (Supplementary
Figure S2). However, their numbers remained lower than
Figure 5. Circulating human CD4+ T cell subsets and cytokines in PB of PBMC, Th17 coinjected, and Th0 coinjected mice at day +14 after transplantation. NSG mice
were irradiated (2.5 Gy total body irradiation) and then underwent transplantation with 2£ 106 PBMCs alone (PBMC mice), with 1£ 106 PBMCs combined with
1£ 106 Th17-polarized cells (Th17 coinjected mice), or with 1£ 106 nonpolarized Th0 cells (Th0 coinjected mice) from the same donor. Peripheral blood samples
were collected at day +14 after transplantation for luminex and ﬂow cytometry analyses. (A to C) Frequencies of CD4+ and CD8+ T cell subsets (A), cytokine serum con-
centrations (B), and frequencies of IFNg- and TNFa-expressing cells (C) for Th17 coinjected mice. Data are median with interquartile range. Data were combined from
3 replicate experiments (A and C) or were from a single experiment (B) (analysis not performed for Th0 coinjected mice). (D) Representative FACS plots from a Th17
coinjected mouse. Global P values (1-way ANOVA) are shown, along with 2-by-2 group comparisons with the Scheffe post hoc procedure (*P< .05). P values in paren-
theses refer to a multivariate Cox model adjusted for PBMC donor and mouse sex and weight. Prior logarithmic transformation was applied for percentage of Tregs.
Black circles denote PBMC mice; gray squares, Th17 coinjected mice; white triangles, Th0 coinjected mice.
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titers of IFNg and TNFa and found no differences between Th17
coinjected and PBMC mice (Figure 5B). Low IL-2 titers were
detectedD31X X, which were higher in the Th17 coinjected mice
(Figure 5B).
PB samples were also collected at day +21 in surviving
mice (Supplementary Figure S3). At this time point, absolute
numbers of CD4+ T cells equilibrated among groups, and the
sole remaining difference between groups was in the propor-
tion of IL-17A+CD4+ cells. Although this proportion declined
from day +14 to day +21, it remained signiﬁcantly higher in
Th17 coinjected mice compared with PBMC and Th0 coin-
jected mice at this latter time point (Supplementary
Figure S3). Taken together, these observations suggest that in
vitro Th17-polarized human cells engrafted and persisted in
NSG mice.
Characterization of Human T Cells in Spleen and xGVHD
Target Organs of Mice Cotransplanted with PBMC and Th17-
Polarized Cells
We further assessed the composition of human T cells inﬁltrat-
ing spleen, BM, liver, and lungs of PBMC mice, Th17 coinjected
mice, and Th0 coinjected mice at day +14 post-transplantation.
We observed higher CD4+/CD8+ T cell ratios in BM, liver, and lungs
of Th17 coinjected and Th0 coinjected mice compared with PBMCmice (Figure 6A). In contrast, the spleen CD4+/CD8+ T cell ratio
was not higher in Th17 coinjected mice compared with PBMC
mice, and no signiﬁcant difference was observed in absolute num-
bers of spleen-inﬁltrating CD4+ T cells between Th17 coinjected
and PBMCmice (Figure 6A and B). In the Th17 coinjected animals,
a signiﬁcant fraction of organ-inﬁltrating CD4+ T cells were
IL-17A+ (median of 11% in BM, 12% in liver, and 10% in lungs),
whereas only low levels of IL-17A+ were detected in organ-
derived CD4+ cells from PBMC and Th0 coinjected mice (median
ranging from 3% to 6% and 0 to 1%, respectively, depending on the
organ) (Figure 6C). Consistently with these observations, we
detected higher relative expression of RORC mRNA in target
organs of Th17 coinjected mice (data not shown). Taken together,
these results suggest that Th17-polarized CD4+ cells migrate
toward and/or proliferate in target organs of NSG mice. As
observed in PB, most of IL-17A+CD4+ T cells acquired a double IL-
17A+IFNg+ secreting proﬁle in peripheral tissues (median range of
72% to 85%, depending on the organ) (Figure 6D).
Regarding other CD4+ T cell subsets, the median frequencies
of IL-17A¡IFNg+ (Th1) in Th17 coinjected mice in BM, liver, and
lungs were signiﬁcantly lower than those observed in target
organs of Th0 coinjected mice (Figure 6E). The frequencies of
CD4+CD25+FOXP3+ Tregs in target organs were low in all groups,
with higher proportions in PBMC mice (Figure 6F). Finally, we
observed higher proportions of TNFa+CD4+ cells in target organs
Figure 6. Human T cells in spleen and xGVHD target organs of PBMC, Th17 coinjected, and Th0 coinjected mice at day +14 after transplantation. NSG mice were irra-
diated (2.5 Gy total body irradiation) and then underwent transplantation with 2£ 106 PBMCs alone (PBMC mice), with 1£ 106 PBMCs combined with 1£ 106 Th17-
polarized cells (Th17 coinjected mice), or with 1£ 106 nonpolarized Th0 cells (Th0 coinjected mice) from the same donor. At day +14, mice were sacriﬁced and PB,
spleen, BM, liver, and lungs were harvested for ﬂow cytometry analysis. (A to D) CD4+/CD8+ human T cell ratio (A), absolute CD4+ and CD8+ T cell counts in spleen (B),
frequencies of IL-17A+ cells among CD4+ T cells (C), and frequencies of IFNg- and TNFa-expressing cells (D) for Th17 coinjected mice. Data are median with interquar-
tile range. (E to H) Other CD4+ and CD8+ T cell subsets. Data are from a single experiment with 1 donor. Global P values (1-way ANOVA) are shown, along with 2-by-2
group comparisons with the Scheffe post-hoc procedure (*P< .05). P values in parentheses refer to a multivariate Cox model adjusted for mouse sex and weight. Prior
logarithmic transformation was applied for the CD4/CD8 T cell ratio in all organs; absolute number of CD8+ T cells in spleen; percentage of IL-17A+CD4+ cells in spleen,
liver, and lungs; and percentage of Tregs in all organs. Black circles denote PBMC mice, gray squares, Th17 coinjected mice; and white triangles, Th0 coinjected mice.
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PBMC mice, although the difference was not signiﬁcant for lungs
of Th17 coinjected mice (Figure 6G). TNFa was expressed by IL-
17A+ (Th17) and IL-17A¡IFNg+ (Th1) cells in high proportions
(Figure 6D). Regarding CD8 populations, no difference was
observed between Th17 coinjected mice and the other 2 groups.
Most of CD8+ T cells in spleen and target organs were
IL-17A¡IFNg+ CD8+ T cells (Tc1) (Figure 6H), and only very low
(<1%) proportions of IL-17A+CD8+ T cells (Tc17) were detected in
all groups (data not shown).
We next performed CD4+IL-17A+ immunohistochemical
staining on liver, lung, and skin specimens harvested from
mice sacriﬁced at day +21 after transplantation (see Supple-
mentary Figure S4). In all groups of mice, we found a mild
inﬁltration of CD4+IL-17A+ double-positive cells in lungs and
skin (dermis) of mice, but almost a total absence of CD4+IL-
17A+ cells in liver. We also observed a trend for a higher num-
ber of inﬁltrating CD4+IL-17A+ cells in lungs of Th17 coinjected
mice compared with PBMC and Th0 coinjected mice, although
the difference did not reach statistical signiﬁcance. No differ-
ence in total CD4+ and CD8+ cell inﬁltration was observed
between groups (data not shown).Impact of PBMCs Cotransplanted with Th17-Polarized versus
Th1-Polarized Cells on xGVHD
We next investigated the impact on xGVHD of PBMCs
(1£ 106 per mouse) cotransfer with Th17-polarized cells
(1£ 106 per mouse) compared with cotransfer with Th1-polar-
ized cells (1£ 106/ mouse, Th1 coinjected group). Characteristics
of in vitro polarized Th1 cells are presented in Figure 7A. Th17
coinjection was associated with aggravated signs of xGVHD and
with lower survival compared with Th1 coinjection (P = .07, uni-
variate analysis; P = .011, multivariate analysis) (Figure 7B).
Transplantation of Th17-Polarized Cells Alone (Not Combined
with PBMCs)
To evaluate whether Th17-polarized cells could induce lethal
xGVHD by themselves, we compared mice transplanted with
Th17-polarized cells alone (2£ 106 per mouse) and mice trans-
planted with Th0-nonpolarized cells (2£ 106 per mouse) or
Th1-polarized cells (2£ 106 per mouse) as well as a control
group of PBMC mice (2£ 106 per mouse). Although they
engrafted, Th17-polarized cells generated only mild xGVHD by
themselves (as did Th0 and Th1 cells) (Supplementary
Figure S5). In fact, although all PBMC mice died within 50 days
Figure 7. Impact of PBMC cotransplantation with Th17-polarized versus Th1-polarized cells on xGVHD. NSG mice were irradiated (2.5 Gy total body irradiation) and
then underwent transplantation with 1£ 106 PBMCs combined with 1£ 106 Th17-polarized cells (Th17 coinjected mice) or with 1£ 106 nonpolarized Th0 cells (Th0
coinjected mice) from the same donor. (A) Frequencies of IL-17A+ and IL17A¡IFNg+ cells among CD4+ cells (ﬂow cytometry) and relative mRNA expression of RORC
and TBX21 normalized to TBP (RT-qPCR). (B) Survival curves. (C) xGVHD scores. (D) Weight loss. B, C, and D show combined data from 2 replicate experiments with 2
different donors, with 7 Th17 coinjected mice and 7 Th1 coinjected mice. For xGVHD score and % of weight loss, data are shown as mean. P values in parentheses refer
to a multivariate Cox model adjusted for PBMC donor and mouse sex and weight. Gray squares denote Th17 coinjected mice; black diamonds, Th1 coinjected mice.
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and all Th1-transplantedmice survived for>100 days.
Impact of PBMC Cotransplantation with Th17-Polarized Cells
on GVT Effects
We evaluated the growth of THP-1-luc tumors in NSG mice
that underwent transplantation with 1£ 106 freshly isolated
PBMCs (PBMC group) and with 5£ 105 freshly isolated PBMCs
added with 5£ 105 Th17-polarized cells (Th17 coinjection
group), Th1-polarized cells (Th1 coinjection group), or nonpo-
larized CD4+ T cells (Th0 coinjection group) (Figure 8A). As a
positive control, another group of mice received s.c. injections
of THP-1-luc cells without undergoing previous irradiation or
transplantation with human immune cells (THP-1 control
group). Compared with THP-1 control mice, decreased tumor
burdens were observed in mice transplanted with human
immune cells at day +21 (bioluminescent imaging, although
not signiﬁcant for PBMC and Th17 mice) and day +35 (tumor
dissection and weighing) after THP-1-luc injection, suggesting
possible GVT effects (Figure 8B and C). By analyzing the trans-
planted groups, we observed trends for lower bioluminescence
and lower tumor weights at day +35 in Th1 coinjected mice
compared with PBMC mice (Figure 8B and C). These observa-
tions may suggest that GVT effects could have been reinforced
by the addition of Th1-polarized cells. In contrast, no difference
was observed between Th17 coinjected and PBMCmice at both
time points, suggesting that PBMC enrichment with Th17-
polarized cells did not increase GVT effects.
No mouse died because of xGVHD during the experiment.
Some cutaneous lesions (alopecia and skin inﬂammation) were
observed. These skin lesions developed in several mice of each
transplanted group but were more extensive in Th17 coin-
jected mice (Supplementary Figure S6).
DISCUSSION
The role of Th17 cells in the NSG xGVHD model has not yet
been fully explored. In this study, we investigated the impact
of PBMC cotransfer with in vitro Th17-polarized human CD4+ Tcells. Compared with mice transplanted with PBMCs only or
cotransplanted with PBMCs and Th0 cells, Th17 coinjected
mice displayed higher frequencies and higher absolute num-
bers of circulating IL-17A+CD4+ T cells in PB, as well as higher
frequencies of inﬁltrating IL-17A+CD4+ T cells in BM, liver, and
lungsD32X XD33X X. Although no in vivo tracking of human lymphocytes in
NSG mice was achievable, these results could provide indirect
evidence that in vitro polarized Th17 cells engrafted and
migrated toward target organs after transfer in recipient mice.
Interestingly, the proportion of circulating IL-17A-expressing
cells among CD4+ T cells declined from day +14 to day +21 in
Th17 coinjected mice, and only a mild CD4+IL-17A+ cell inﬁltra-
tion in organs was detected by immunohistochemistry on day
+21. Although a genuine loss of the population cannot be pre-
cluded, these data are in accordance with observations
reported by Gartlan et al. [11] in a mouse-to-mouse Th17
“fate-mapping” reporter model. These authors demonstrated
that the expression of IL-17A protein in Th17 cells declined
during the progression of GVHD, suggesting that IL-17A proba-
bly is not the most reliable marker for tracking Th17 cells in
vivo. On the other hand, although most Th17-polarized cells
did not produce IFNg in vitro, we observed that the majority of
IL-17A+CD4+ T cells coexpressed IFNg in vivo in recipient mice,
and that the proportion of IL-17A+IFNg+-double-expressing
cells increased from day +14 to day +21. These data are consis-
tent with the concept that Th17 cells have a plastic expression
proﬁle and can convert to a “Th1-like” phenotype in vivo in
the presence of the antigen and several speciﬁc cytokines, such
as IFNg itself, IL-12, and IL-23 [5,11,43,47,48]. Moreover, IFNg
expression by Th17 cells is currently recognized as a hallmark
of enhanced pathogenicity and inﬂammatory properties
[49,50]. Thus, our results suggest that in addition to their
robust engraftment, in vitro polarized Th17 cells were able to
acquire a pathogenic proﬁle in recipient mice.
We further observed that, compared with mice injected
with PBMCs only, mice coinjected with PBMCs and
Th17-polarized cells experienced worse xGVHD and poorer
survival. In contrast, no signiﬁcant differences in xGVHD
Figure 8. Impact of PBMC cotransplantation with Th17-polarized cells on GVT effects. NSG mice were irradiated (2.5 Gy total body irradiation) and then underwent
transplantation with 1£ 106 PBMCs alone (PBMCmice), with 5£ 105 PBMCs combined with 5£ 105 Th17-polarized cells (Th17 coinjected mice), with 5£ 105 nonpo-
larized CD4+ T cells (Th0 coinjected mice), or with 5£ 105 Th1-polarized cells (Th1 coinjected mice) from the same donor. At 14 days after transplantation, mice were
given an s.c. injection (in the left ﬂank) of 1£ 106 THP-1-luc cells suspended in Matrigel solution. As a positive control, another group of mice also received an s.c.
injection of THP-1-luc cells, without previous irradiation or transplantation with human immune cells (THP-1 control group). Tumor growth was evaluated by mea-
suring bioluminescence at day +21 after THP-1-luc injection, and tumors were dissected and weighted at day +49 after THP-1-luc injection (planned sacriﬁce). (A)
Images of 1 representative mouse from each group are shown, with the y-axis indicating photon ﬂux (photons/second) measured from the mouse tumor left side. (B)
Tumor bioluminescence at day +35 after injection of PBMCs with and without Th17, Th1, or Th0 coinjection. (C) Tumor weight at day +60 after injection of PBMCs
with and without Th17, Th1, or Th0 coinjection. Data are from 2 independent experiments with 2 donors, 6 THP-1 mice, 9 PBMC mice, 8 Th17 coinjected mice, 6 Th0
coinjected mice, and 7 Th1 coinjected mice. Global P values (1-way ANOVA) are shown, along with 2-by-2 group comparisons with the Scheffe post-hoc procedure
(*P < .05). P values in parentheses refer to a multivariate Cox model adjusted for PBMC donor. Black circles denote PBMC mice; gray squares, Th17 coinjected mice;
white triangles, Th0 coinjected mice; black diamonds, Th1 coinjected mice.
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coinjected mice, suggesting that xGVHD exacerbation in
mice cotransplanted with in vitro Th17-polarized cells was
not simply linked to the transplantation of a greater number
of CD4+ T cells or to T cell preactivation during the culture
process. These observations are in line with those reported
in several mouse-to-mouse experiments. Using different
murine models of allogeneic aGVHD, Iclozan et al. [8] andCarlson et al. [7] demonstrated that cotransfer of T cell-
depleted BM cells with in vitro differentiated mouse Th17
cells exacerbated aGVHD to a greater degree than cotransfer
with puriﬁed nonactivated CD4+ CD25¡ T cells [7] or Th0
cells [8]. Interestingly, in our experiment, in vitro generated
Th0 cells contained a signiﬁcant proportion of IFNg+CD4+
cells, and most CD4+ T cells in PB and peripheral organs in
Th0 coinjected mice were IFNg+CD4+ (Th1) cells.
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in vitro Th1-polarized cells compared with cotransfer with
Th17-polarized cells. We observed lower xGVHD severity and
lethality in Th1 coinjected mice compared with Th17 coin-
jected mice. Consistent with our observations, Iclozan et al. [8]
also reported that murine Th17-polarized cells generated sig-
niﬁcantly more inﬂammation and damage in recipient target
organs than Th1-polarized cells. Taken together, these data
indicate that Th17 have a greater ability to exacerbate xGVHD
than Th0 or Th1 cells in cooperation with PBMCs.
On the other hand, transplantation of Th17-polarized cells
alone (not combined with PBMCs) revealed that Th17 cells did
not generate lethal xGVHD by themselves, nor did Th0 and
Th1 cells. This ﬁnding is in accordance with previous reports in
NSG mice showing that puriﬁed CD4+ T cells only mediated
delayed and mild xGVHD [23,30,33,35,51]. Thus, although
Th17 cells were not sufﬁcient to individually induce lethal
xGVHD, our experiments using Th17 cotransfer with PBMCs
demonstrated that these cells nevertheless could exacerbate
the disease.
Regarding the clinical phenotype of xGVHD mice, we
noticed that some mice surviving beyond 40 days after trans-
plantation developed cutaneous lesions (alopecia), which
seemed to be more frequent and more extensive in the Th17
coinjected mice. Histopathological analyses revealed epider-
mal hyperplasia, epidermal and follicular dyskeratosis, basal
cell layer vacuolization and dermal ﬁbrosis. These ﬁndings are
in line with several other experimental models reporting sub-
stantial IL-17A-dependent pathological cutaneous lesions
[7,23]. Reports from experiments in mouse-to-mouse models
of GVHD have also suggested that the lung may be highly sen-
sitive to Th17-mediated inﬂammation, and that in vitro polar-
ized murine Th17 cells are able to produce more severe lung
pathological lesions than Th0 or Th1 cells [7,8]. Using our
humanized xGVHD model, we similarly observed a trend for
aggravated histopathological xGVHD lesions compared with
PBMC and Th0 coinjected mice. However, considering the
small sample size in our experiment, this remains to be con-
ﬁrmed in further studies.
Our present results do not reveal the mechanisms by
which Th17 coinjection exacerbate xGVHD severity and
lethality. Among the various hypotheses that have been
advanced, previous observations from murine T cell transfer
experiments have suggested a superior ability of Th17 cells
to expand and inﬁltrate target organs compared with other
Th subsets, such as Th1 cells. [8] In line with this, our CFSE
experiments revealed an accelerated cell division rate in PB
and target organs for human Th17-polarized cells compared
with fresh CD4+ T cells, Th0 cells, and Th1 cells early
(day +3) after their transfer in NSG mice. However, we did
not observe higher chimerism in PB at days +14 and +21
in Th17 coinjected mice. Data from antitumor and antiviral
immunity experiments have also revealed that Th17 cells
could have a unique ability to promote CD8+ T cell priming
and cytotoxicity in target tissues through both direct
[52-54] and indirect (via the recruitment of dendritic cells)
[52,55] mechanisms.
Whether Th17 cells can in fact enhance CD8+ T cell cytotox-
icity during xGVHD in our model remains to be explored in fur-
ther studies.
Th17 cells are known to secrete an array of inﬂammatory
effector cytokines that are not typically produced by Th1 cells,
among which IL-17A is the most well known. We detected
increased IL-17A serum titers as well as increased frequencies
of IL-17A-expressing CD4+ T cells in target organs in Th17coinjected mice at day +14 after transplantation. Several previ-
ous studies have reported that disruption of IL-17A signaling
(either genetically or via neutralizing antibodies) can markedly
decrease skin and lung GVHD pathology [7,23,56]. IL-17 has
been shown to be capable of causing direct [57] and indirect tis-
sue damage, the latter via the induction of additional cytokines
and chemokines, which in turn mobilize a variety of inﬂamma-
tory leukocytes (ie, neutrophils, dendritic cells, macrophages,
and other lymphocytes, such as CD8+ T cells) in target tissues
[23,56,58-60]. Indeed, in a mouse-to-mouse allogeneic model,
Hill et al. [56] found that the major effect of IL-17A in Th17-
mediated aGVHD skin lesions appeared to be as a chemoattrac-
tant for macrophages and neutrophils. Recently, Ito et al. [23]
observed similar conclusions in their humanized model of CD4+
T cell-mediated cutaneous xGVHD in NOG mice. They reported
that inhibition of human IL-17A with secukinumab (an anti-
huIL-17A monoclonal antibody) reduced neutrophil inﬁltration
into the skin and prevented Th17-mediated skin inﬂammation.
Taken together, these ﬁndings support a potential role of IL-17A
in Th17-mediated skin and lung GVHD pathology. One speciﬁc-
ity of the xGVHD NSG model is the gut-sparing effect [27]. In
contrast, the intestine is a major target for aGVHD in humans.
IL-17A has been reported to play complex roles in gut immu-
nity, with both proinﬂammatory and protective effects [61]. Pre-
clinical and clinical studies in psoriasis and inﬂammatory bowel
disorders have revealed risks of induction or exacerbation of
colitis, as well as susceptibility to infections, when using IL-17A-
neutralizing approaches [20-22]. Thus, caution is warranted
when considering IL-17A blockade for treating patients with
aGVHD.
Other cytokines linked to Th17 functions, such as IL-17F, IL-
21, IL-22, and GM-CSF [10], also might have contributed to
Th17-mediated xGVHD, but these were not explored in this
study.
Although Th17 cooperated with PBMCs in xGVHD reactions,
Th17 cotransfer with PBMCs did not reinforce GVT effects
against human THP-1 cells. The possibility that CD4+ T cells
have a limited role in GVT reactions compared with CD8+ T cells
cannot be excluded [62,63]. Moreover, Th17 cells have been
reported to alternatively exert either protumor or antitumor
effects, partly in line with their highly plastic developmental
program, which gives them the ability to transdifferentiate
toward functional distinct phenotypes, including Th17/Th1-like
cells as well as suppressive IL-10+ FOXP3+ Th17 cells [64-68].
The context may be important, and there is a possibility that the
complex tumor microenvironment can govern Th17 cell fate.
However, our results must be interpreted with caution, consid-
ering the complex and artiﬁcial nature of our model with s.c.
injection of human THP-1 cells.
To the best of our knowledge, only a few experimental
xGVHD models allow the exploration of human Th17 cell
behavior in vivo. In addition to the model of Th17-mediated
cutaneous xGVHD recently developed by Ito et al. [23], which
does not allow for investigation of the impact of Th17 on
CD8+ T cells, we believe that the model we present here may
offer a relevant preclinical platform for exploring pathological
pathways mediated by human Th17 in GVHD and GVT immu-
nobiology. However, we must concede some limitations of
our model that suggest the need for a caution when interpret-
ing our results. The ﬁrst of these was the difﬁculty in generat-
ing highly enriched and puriﬁed populations of
IL-17A-expressing cells from human naive CD4+ T cells in
vitro. In accordance with our results, Kleinewietfeld et al. [42]
also reported a median IL-17A+CD4+ T cell yield of 5% to 35%
after in vitro differentiation from human naive T cells. These
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experiment that showed stable generation of highly puriﬁed
Th17 from naive mouse CD4+ T cells [7,43-45], supporting the
concept of differences between human and mouse Th17
immunology. Nevertheless, although they contained only a
limited fraction of IL-17A+ expressing cells, Th17-polarized
cells had a major impact on xGVHD in our study. On the other
hand, the fact that the in vitro generated population of human
Th17-polarized CD4+ T cells was heterogeneous in nature and
not a pure subset of Th17 lymphocytes may raise concerns
regarding their actual implications in xGVHD exacerbation.
We believe that experiments with the comparative group of
Th0 coinjected mice showing that xGVHD was not exacer-
bated by the cotransfer of Th0 cells and that D3 4X Xthe main differ-
ences between Th0 coinjected and Th17 coinjected mice
concerned IL-17A+CD4+ frequencies D 35 X X may raise some argu-
ments regarding the fact that Th17 cells were likely the effec-
tor cells responsible for aggravated xGVHD.
Finally, along with the impact of Th17 coinjection, results
from the ﬁrst set of our experiments (PBMC versus Th17 coin-
jection, 4 different donors) also suggested signiﬁcant interdo-
nor variability in xGVHD severity and lethality. This ﬁnding is
in accordance with previous reports from our group [34] and
others [29]. Compared with mouse-to-mouse allogeneic mod-
els of aGVHD characterized by ﬁxed genetic and immunologic
disparities between donors and recipients (within a deter-
mined model), this xGVHD model uses human PBMC donors
with high genetic diversity. Moreover, whereas mice are bred
and housed in pathogen-free conditions, human donors are
exposed to pathogens than can variously inﬂuence their
immunity (eg, the relationship between CMV infection and
GVHD [69]). However, speciﬁc predictors of donor xenoreac-
tivity in this model remain to be determined.
In conclusion, our current observations point out the poten-
tial functional implication of human Th17 cells in xGVHD
immunopathology and support exploring Th17 targeted strate-
gies for intervention to reduce aGVHD.
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